bioecon Member area
Technology · Services, governance & capital / Insurance & risk

Clinical-trial insurance brokerage

Specialist insurance brokers who structure and place subject-injury, professional-indemnity and product-liability coverage for a clinical trial program, harmonizing the statutorily-required local insurance of every country a trial runs in into a single manageable placement.

Medicine & Pharmaceuticals Risk: low Pharma & biologics US · EU verified 2026-08-18 · 5 Sources (0 independent)

1 · What it gives

Clinical-trial insurance brokerage places the coverage a sponsor is legally required to carry — or contractually obligated to provide a site under a Clinical Trial Agreement — before a study can enroll its first subject. Newline Group, a Lloyd’s-market underwriting manager based in London, runs a dedicated Clinical Trials product line offering life-of-trial policies of up to ten years’ duration, country-specific annual “all trial” policies, and bespoke multi-country or global master difference-in-conditions/difference-in-limits programs. Marsh, one of the world’s largest insurance brokers, is named among the leading placement houses for clinical-trial coverage by independent market comparisons. Howden, a UK-headquartered global broker, published a 2026 sector report on how insurance can support the UK pharma industry through its current transition, reflecting its active life-sciences practice. Gallagher’s Life Sciences practice published a dedicated whitepaper, “Mitigating Risks Through Clinical Trial Funding Insurance,” alongside a Winter 2026 market summary specifically covering pharmaceutical, biotechnology, medical-device, CRO and CMO clients. WTW (Willis Towers Watson) publishes ongoing analysis of clinical-trial insurance underwriting trends, including the growing role of trial medical-expense coverage and 2025 rate predictions for life-sciences products and professional liability.

The key directions of clinical-trial insurance brokerage are:

  1. Subject-injury and liability placement: structuring coverage for bodily injury and medical expenses incurred by trial participants, alongside sponsor and site professional-indemnity and product-liability exposure.
  2. Multi-jurisdiction program harmonization: placing a single master or difference-in-conditions/difference-in-limits policy that satisfies the differing statutory clinical-trial insurance requirements of every country a study runs in.
  3. Life-of-trial and annual policy structuring: choosing between a single policy covering a trial’s full multi-year duration versus renewable annual “all trial” country-specific policies, depending on program length and portfolio size.
  4. Site indemnification advisory: advising sponsors and research sites on the insurance and indemnification terms of the Clinical Trial Agreement or Master Services Agreement before a site signs on.

Sectoral value chain#

[Trial protocol & jurisdiction scoping] ──> [Coverage structuring & underwriter placement] ──> [Policy issuance across trial countries]
                                                                    │
                                                        (Site indemnification review)
                                                                    │
                    [Claims handling to closure] <──── [Ongoing program renewal/amendment] <─── [Subject-injury claim intake]

Value chain levels#

LevelDescriptionKey inputs/outputs
Protocol & jurisdiction scopingReviewing the trial protocol and the list of countries/sites it will run in to determine the statutory insurance requirements that apply.In: Trial protocol, site/country list.
Out: Jurisdictional coverage requirement matrix.
Coverage structuring & placementStructuring the policy (life-of-trial vs. annual, master vs. local) and placing it with underwriters.In: Jurisdictional coverage requirement matrix.
Out: Placed insurance program.
Policy issuance across trial countriesIssuing the local policy documentation required in each jurisdiction under the master program.In: Placed insurance program.
Out: Country-specific policy documents.
Site indemnification reviewAdvising sponsor and site on the Clinical Trial Agreement’s insurance and indemnification terms before signing.In: Country-specific policy documents, draft CTA/MSA.
Out: Reviewed indemnification terms.
Subject-injury claim intakeReceiving and triaging a reported subject-injury or liability event during trial conduct.In: Reported adverse/injury event.
Out: Intake claim file.
Claims handling to closureManaging the claim through investigation, negotiation and settlement or denial, and feeding lessons into program renewal.In: Intake claim file.
Out: Closed claim, renewal/amendment input.

Cross-cutting technologies of the sector:

  • Clinical-trial liability placement: specialist insurance-broking practice that structures and places subject-injury, professional-indemnity and product-liability coverage for a specific clinical trial program across the jurisdictions it runs in.
  • Multi-country trial insurance programs: master or difference-in-conditions/difference-in-limits insurance policies that harmonize local, statutorily-required clinical-trial coverage across every country a sponsor’s trial operates in under one program.

2 · What it replaces 0 · matched by industry

No graded substitution linked yet.

3 · How to implement 6 steps

  1. 1
    Protocol and jurisdiction scoping
    The broker reviews the trial protocol and the list of countries and sites it will run in to determine which statutory clinical-trial insurance requirements apply.
  2. 2
    Coverage structuring and underwriter placement
    The broker structures the policy — life-of-trial or annual, master program or local — and places it with one or more underwriters, often via the Lloyd’s market for specialist life-sciences risk.
  3. 3
    Policy issuance across trial countries
    Local policy documentation required in each jurisdiction is issued under the umbrella of the master program.
  4. 4
    Site indemnification review
    The broker or sponsor’s risk team reviews the Clinical Trial Agreement or Master Services Agreement’s insurance and indemnification terms before a site signs.
  5. 5
    Subject-injury claim intake
    A reported subject-injury or liability event during trial conduct is received and triaged into a claim file.
  6. 6
    Claims handling to closure
    The claim is investigated, negotiated and settled or denied, with lessons feeding back into the next program renewal or amendment.

4 · Who delivers

Matched suppliers (matched automatically)

TsumuraJapanProduceractive
BiohavenUnited StatesResearch / RTOactive
Recursion PharmaceuticalsUnited StatesResearch / RTOactive
GenmabDenmarkProduceractive
Nostoc BiotechSpainProduceractive
Nada - ندىSaudi ArabiaProduceractive
FreseniusGermanyProduceractive
VinaseedVietnamResearch / RTOactive
Milwhite, Inc.United StatesResearch / RTOactive

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Newline Group🇬🇧 UKDedicated Clinical Trials product line (Lloyd’s)Life-of-trial policies to 10 years, multi-country DIC/DILcommercial
Marsh🇺🇸 USAClinical-trial insurance placementLeading global placement scalecommercial
Howden🇬🇧 UKLife-sciences insurance brokingUK pharma-sector transition advisorycommercial
Gallagher🇺🇸 USALife Sciences practice, clinical-trial funding insuranceDedicated whitepaper + market-summary researchcommercial
WTW🇬🇧 UKClinical-trial insurance underwriting analysisTrial medical-expense coverage evolution trackingcommercial

5 · Rules & route to market

United States

The United States hosts two of the largest global insurance-broking houses with dedicated life-sciences practices covering clinical-trial placement.

Marsh’s placement scale, Gallagher’s dedicated Life Sciences whitepaper#

  • Marsh: named among the leading clinical-trial insurance placement brokers in independent market comparisons, leveraging its position as one of the world’s largest insurance brokers to place complex, cross-border trial programs.
  • Gallagher: its Life Sciences practice publishes dedicated clinical-trial funding insurance guidance and a recurring life-sciences insurance market summary covering pharmaceutical, biotech, medical-device, CRO and CMO clients specifically.

European Union

The European Union — via UK-headquartered brokers and Lloyd’s-market underwriters — hosts the deepest specialist clinical-trial insurance capacity, including the sector’s dedicated Lloyd’s product line.

Newline’s dedicated Lloyd’s product line, Howden’s UK life-sciences transition report, WTW’s underwriting-trend analysis#

  • Newline Group: a Lloyd’s-market underwriting manager running a dedicated Clinical Trials product line — life-of-trial policies up to ten years, country-specific annual “all trial” policies, and bespoke multi-country or global master difference-in-conditions/difference-in-limits programs.
  • Howden: published a 2026 report on how insurance can support the UK pharmaceutical and life-sciences sector through its current transition, reflecting an active dedicated life-sciences broking practice.
  • WTW (Willis Towers Watson): publishes ongoing analysis of clinical-trial insurance underwriting trends, including trial medical-expense coverage evolution and life-sciences product/professional-liability rate predictions.

China

China is covered qualitatively rather than by a live-screened Chinese vendor: candidate Chinese clinical-trial insurance brokers searched during this screen returned no confirming 2026 source, so no Chinese company is tabled below. Multinational sponsors running trials in China typically place local statutorily-required coverage through the same global brokers’ China offices or local co-insurance partners, rather than through a distinct domestic clinical-trial-insurance specialist confirmed on this screen.

No confirmed domestic specialist; global brokers’ China offices place local statutory coverage#

  • Global broker China offices: multinational sponsors running China trial sites typically route the locally-required clinical-trial insurance placement through the same global brokers’ China operations rather than a distinct domestic specialist.
  • Domestic gap: no China-headquartered clinical-trial insurance brokerage confirmed by a live 2026 source was found during this screen.

6 · Money: tenders & grants

GrantNIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
National Institutes of Health · United States
Jul 5, 2029
955 days
GrantFirst in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based …
National Institutes of Health · United States
Oct 15, 2027
326 days
GrantBlueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the …
National Institutes of Health · United States
Aug 18, 2027
268 days
GrantDevelopment of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not …
National Institutes of Health · United States
Jan 25, 2028
428 days
GrantAgriculture and Food Research Initiative Competitive Grants Program Foundational and Applied Science Program
National Institute of Food and Agriculture · United States
Dec 31, 2026
38 days

7 · Tech stack & innovations

The clinical-trial insurance brokerage “technology stack” is less software than structuring know-how, applied through a small set of recurring policy mechanisms:

  1. Difference-in-conditions/difference-in-limits (DIC/DIL) master programs:
    • Newline’s global master programs harmonize varying local statutory minimums into one placement, avoiding a patchwork of separately negotiated local policies.
  2. Life-of-trial vs. annual policy structuring:
    • Brokers choose between a single policy spanning a trial’s full multi-year duration and renewable annual all-trial policies, trading premium certainty against flexibility as a program’s country footprint changes.
  3. Sector-specific market-trend research feeding placement strategy:
    • Gallagher and WTW both publish recurring life-sciences insurance market analysis that directly informs how a given trial program is structured and timed for placement.

Sources 5 · 0 independent · 5 producer sites

Producers' own sites 5

  1. Newline producer checked 2026-08-12 · link not kept
  2. Marsh producer checked 2026-08-11 · link not kept
  3. Howden producer checked 2026-08-11 · link not kept
  4. Gallagher producer checked 2026-07-13 · link not kept
  5. Wtw producer checked 2026-07-31 · link not kept